CR20140154A - Compuestos para inhibir la progresión mitotica - Google Patents

Compuestos para inhibir la progresión mitotica

Info

Publication number
CR20140154A
CR20140154A CR20140154A CR20140154A CR20140154A CR 20140154 A CR20140154 A CR 20140154A CR 20140154 A CR20140154 A CR 20140154A CR 20140154 A CR20140154 A CR 20140154A CR 20140154 A CR20140154 A CR 20140154A
Authority
CR
Costa Rica
Prior art keywords
mythical
progression
inhibit
compounds
mythical progression
Prior art date
Application number
CR20140154A
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140154(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CR20140154A publication Critical patent/CR20140154A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CR20140154A 2006-11-16 2014-04-04 Compuestos para inhibir la progresión mitotica CR20140154A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
CR20140154A true CR20140154A (es) 2014-07-23

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
CR10782A CR10782A (es) 2006-11-16 2009-05-08 Compuestos para inhibir la progresion mitotica
CR20140154A CR20140154A (es) 2006-11-16 2014-04-04 Compuestos para inhibir la progresión mitotica
CR20140544A CR20140544A (es) 2006-11-16 2014-11-27 Compuestos para inhibir la progresión mitotica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10782A CR10782A (es) 2006-11-16 2009-05-08 Compuestos para inhibir la progresion mitotica

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140544A CR20140544A (es) 2006-11-16 2014-11-27 Compuestos para inhibir la progresión mitotica

Country Status (34)

Country Link
US (7) US8026246B2 (es)
EP (4) EP2086981B1 (es)
JP (3) JP5102839B2 (es)
KR (2) KR101110458B1 (es)
CN (2) CN103483343B (es)
AR (1) AR064246A1 (es)
AT (1) ATE556076T1 (es)
AU (1) AU2007322046B2 (es)
BR (1) BRPI0718803B8 (es)
CA (1) CA2669680C (es)
CL (1) CL2007003244A1 (es)
CR (3) CR10782A (es)
CY (1) CY1112828T1 (es)
DK (2) DK2086981T3 (es)
EA (1) EA015779B1 (es)
ES (3) ES2528793T3 (es)
GE (1) GEP20125459B (es)
HR (2) HRP20120490T1 (es)
IL (1) IL198690A0 (es)
MA (1) MA30988B1 (es)
MX (3) MX2009004670A (es)
MY (1) MY153243A (es)
NO (1) NO343338B1 (es)
NZ (3) NZ577042A (es)
PH (1) PH12012502057B1 (es)
PL (2) PL2497772T3 (es)
PT (2) PT2497772E (es)
RS (2) RS52313B (es)
SG (2) SG10201503350TA (es)
SI (2) SI2497772T1 (es)
TW (1) TWI401255B (es)
UA (1) UA94129C2 (es)
WO (1) WO2008063525A1 (es)
ZA (1) ZA200903279B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50568B8 (sr) 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
MX2011006725A (es) * 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) * 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
JP2018502089A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
US10221158B2 (en) 2015-09-09 2019-03-05 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CA3247864A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
IL317823A (en) 2022-06-30 2025-02-01 Lilly Co Eli KRAS G12C inhibitor for cancer treatment
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW486480B (en) 1996-03-08 2002-05-11 Zeneca Ltd Azolobenzazepine derivatives and compositions and method of use thereof
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
RU2198885C2 (ru) 1997-09-29 2003-02-20 Мейдзи Сейка Кайся Лтд. Производные трициклического триазолобензазепина, способы их получения, фармацевтическая композиция и способ лечения аллергических заболеваний, промежуточные соединения и способы их получения
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
RS50568B8 (sr) 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
US20080167292A1 (en) 2008-07-10
SG10201503350TA (en) 2015-06-29
JP5452811B2 (ja) 2014-03-26
MX348568B (es) 2017-06-20
EP2944639A1 (en) 2015-11-18
PT2497772E (pt) 2015-02-05
DK2086981T3 (da) 2012-08-06
US9988384B2 (en) 2018-06-05
TWI401255B (zh) 2013-07-11
AU2007322046A1 (en) 2008-05-29
CN101547924A (zh) 2009-09-30
CR20140544A (es) 2015-01-12
US20190031662A1 (en) 2019-01-31
TW200829589A (en) 2008-07-16
HK1175778A1 (en) 2013-07-12
CN103483343B (zh) 2016-06-01
NZ597252A (en) 2013-06-28
ATE556076T1 (de) 2012-05-15
SI2086981T1 (sl) 2012-12-31
IL198690A0 (en) 2010-02-17
EP2944639B1 (en) 2017-01-04
US20150166545A1 (en) 2015-06-18
CN101547924B (zh) 2013-09-25
EP2497772A1 (en) 2012-09-12
KR20090091173A (ko) 2009-08-26
SI2497772T1 (sl) 2015-03-31
UA94129C2 (ru) 2011-04-11
HK1175777A1 (en) 2013-07-12
EA015779B1 (ru) 2011-12-30
MA30988B1 (fr) 2009-12-01
PL2086981T3 (pl) 2012-09-28
CA2669680A1 (en) 2008-05-29
CA2669680C (en) 2012-04-10
US20210214361A1 (en) 2021-07-15
NZ611898A (en) 2015-01-30
CY1112828T1 (el) 2016-02-10
US20110312942A1 (en) 2011-12-22
PH12012502057A1 (en) 2015-09-14
WO2008063525A1 (en) 2008-05-29
US10836766B2 (en) 2020-11-17
ES2528793T3 (es) 2015-02-12
KR101342014B1 (ko) 2013-12-19
BRPI0718803B8 (pt) 2021-05-25
KR20110113210A (ko) 2011-10-14
CR10782A (es) 2009-06-24
AR064246A1 (es) 2009-03-25
RS53788B1 (sr) 2015-06-30
SG176443A1 (en) 2011-12-29
EP2086981B1 (en) 2012-05-02
JP5102839B2 (ja) 2012-12-19
US11958855B2 (en) 2024-04-16
HK1134672A1 (en) 2010-05-07
GEP20125459B (en) 2012-03-26
EP2497773B1 (en) 2015-02-25
NO20091864L (no) 2009-06-15
JP2014055166A (ja) 2014-03-27
EP2497772B1 (en) 2014-10-29
HRP20120490T1 (hr) 2012-07-31
CL2007003244A1 (es) 2008-04-04
MX343391B (es) 2016-11-04
EP2086981A1 (en) 2009-08-12
MY153243A (en) 2015-01-29
US8026246B2 (en) 2011-09-27
RS52313B (sr) 2012-12-31
AU2007322046B2 (en) 2012-04-05
US20110312943A1 (en) 2011-12-22
BRPI0718803A2 (pt) 2013-12-03
BRPI0718803B1 (pt) 2020-11-17
NO343338B1 (no) 2019-02-04
ES2384123T3 (es) 2012-06-29
US20240400567A1 (en) 2024-12-05
PH12012502057B1 (en) 2018-10-24
ZA200903279B (en) 2010-07-28
HRP20150047T1 (en) 2015-03-13
JP2012006965A (ja) 2012-01-12
ES2537451T3 (es) 2015-06-08
HK1217699A1 (en) 2017-01-20
JP2010510215A (ja) 2010-04-02
NZ577042A (en) 2012-03-30
DK2497772T3 (en) 2015-01-19
KR101110458B1 (ko) 2012-03-13
EP2497773A1 (en) 2012-09-12
PL2497772T3 (pl) 2015-05-29
EA200970486A1 (ru) 2009-10-30
US9765076B2 (en) 2017-09-19
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
CN103483343A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
CR20140154A (es) Compuestos para inhibir la progresión mitotica
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0817473A2 (pt) plataforma de aplicativo para executar aplicativos
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
DE602006011058D1 (de) Kontinuierliches backup
DE602007011793D1 (de) Biaryl-ether-harnstoffverbindungen
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0811264A2 (pt) Compostos
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0815947A2 (pt) misturas de gipsita para formar sólidos
BRPI0815181A2 (pt) Compostos
BRPI0812961A2 (pt) estrutura para acondicionamento
EP2177529A4 (en) NEW SECRETASE HEMMER
BRPI0814613A2 (pt) Compostos
PL3825306T3 (pl) Związki morfinanu
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0715729A2 (pt) inibidores para glyt-1
ES1065366Y (es) Cubo para friegasuelos
SE530154C8 (sv) Saltblandning
ES1064875Y (es) Estructura para conformar ambientes de exposicion.
BRPI0820430A2 (pt) Composto